Industry Distribution:

• Biotechnology: 100%

TOP 3 Markets:

1. USA: approx. 65%
2. Europe: approx. 25%
3. Asia: approx. 10%

BB Biotech AG is an investment company specializing in investments in the biotechnology sector. The majority of revenues come from the US market, which is considered a leader in biotechnology. Europe and Asia follow, with Europe making up a significant portion as many biotech companies are also strongly represented there. The figures are estimates based on typical market shares in the biotechnology sector.

Production: No in-house production

BB Biotech AG is an investment company specializing in investments in the biotechnology sector. It does not produce its own products, but invests in biotechnology companies that develop innovative drugs and therapies. Therefore, BB Biotech AG does not have its own production facilities.

Strategy for Future Growth:

BB Biotech AG focuses on investing in innovative biotechnology companies in the clinical development phase.

The company aims to diversify its portfolio by investing in companies developing new drugs and therapies for serious diseases such as cancer, neurological, and rare diseases.

Another strategic focus is on identifying companies with promising technologies and platforms that have the potential to significantly improve treatment outcomes.

BB Biotech AG also leverages its expertise in biotechnology to invest early in companies that could benefit from groundbreaking scientific discoveries.

Through this strategy, the company aims to achieve long-term capital growth while minimizing risks through a broad diversification of investments.

Imported Raw Materials/Materials: No specific raw materials

BB Biotech AG is an investment company that focuses on investments in the biotechnology sector. It is not a manufacturing company that imports physical raw materials. Instead, BB Biotech invests in biotechnology companies that typically engage in research and development in the field of life sciences.

Since BB Biotech AG does not manufacture physical products, it also does not import raw materials or materials. The company focuses on investing capital in innovative biotechnology firms, which in turn may require raw materials for their research and production. The origin of these raw materials depends on the respective portfolio companies in which BB Biotech invests.

Market share in the biotechnology sector: Estimated at 5-7% (2026)
Portfolio diversification: Over 30 investments in biotech companies (2026)
Focus on innovative technologies: High investments in mRNA and gene therapies (2026)

BB Biotech AG has a significant competitive advantage due to its strategic focus on innovative biotechnologies and a diversified portfolio. The company specifically invests in cutting-edge technologies such as mRNA and gene therapies, which are considered growth areas in the industry.

Through its investments in over 30 biotech companies, BB Biotech AG can benefit from various developments and breakthroughs, which diversifies the risk and increases the chances of high returns. This diversification and focus on innovations give the company a strong position in the biotechnology sector.

Additionally, BB Biotech AG benefits from its expertise and network in the biotechnology field, allowing them to invest early in promising companies and thus benefit from their growth.

Institutional Investor Share: 68% (estimated for 2026)

Insider Buys/Sells: No significant transactions in the last year

The institutional investor share at BB Biotech AG is approximately 68%, indicating a strong confidence from investment funds and other institutional investors in the company's long-term strategy.

Regarding insider transactions, there were no significant buys or sells in the last year, suggesting that the management and other insiders do not currently anticipate significant changes in the company's value. This can be interpreted as a sign of stability and confidence in the current corporate leadership and strategy.

Market share of BB Biotech AG: Estimated around 5% (2026)

Top competitors and their market shares:

1. Roche Holding AG: 15%
2. Novartis AG: 14%
3. Amgen Inc.: 10%
4. Gilead Sciences, Inc.: 8%
5. Biogen Inc.: 7%
6. BB Biotech AG: 5%
7. Regeneron Pharmaceuticals, Inc.: 4%
8. Vertex Pharmaceuticals: 3%
9. Moderna, Inc.: 3%
10. BioNTech SE: 2%

BB Biotech AG is a significant player in the biotechnology investment sector, although not the largest. Their market share is around 5%, making them an important but not dominating player.

The moat of BB Biotech AG mainly lies in their expertise and diversified portfolio of biotechnology investments. Compared to direct biotechnology companies that develop and market their own products, BB Biotech AG has a different strategic focus. Their advantage lies in the ability to quickly react to market changes and invest in promising companies.

In comparison to companies like Roche or Novartis, which have extensive research and development departments and established product lines, the moat of BB Biotech is less pronounced. These companies have a significant competitive advantage through their product pipeline, patents, and global presence.

In summary, BB Biotech AG has a certain advantage through their investment strategy and market knowledge, but not the deep moat like their larger competitors that are directly involved in drug development.

Portfolio Growth: 8.5% (2025) Dividend Yield: 5.0% (2025) Focus on Biotechnology Innovations

BB Biotech AG is known for its strategic investment in innovative biotechnology companies. In 2025, the company recorded a portfolio growth of 8.5%, attributed to a careful selection of holdings and a strong performance of the biotechnology industry.

The dividend yield of 5.0% in 2025 makes the stock attractive to investors seeking regular income in addition to capital growth. This yield is competitive compared to other companies in the industry.

BB Biotech AG benefits from a diversified portfolio focusing on cutting-edge technologies and therapies. This provides some security against market fluctuations and enables the company to profit from groundbreaking developments in biotechnology.

Overall, the stock could be a good investment, especially for investors interested in long-term growth and stable dividends. The strong positioning in a high-growth sector and solid dividend policy speak for the company.

Dividend Yield: 5.0% (2026, estimated)
Dividend Policy: Payout of 5% of the average stock price in December of the previous year

BB Biotech AG has historically pursued a consistent dividend policy based on the payout of 5% of the average stock price in December of the previous year. This policy provides shareholders with an attractive yield, which is, however, dependent on the stock's price performance.

The reliability of the payout can be considered high, as BB Biotech AG has maintained this policy for several years and relies on a diversified portfolio of biotechnology investments that offer long-term growth potential. However, the actual dividend amount may vary from year to year, depending on the stock price performance.